Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations

Autores
Vinderola, Celso Gabriel; Druart, Céline; Gosálbez, Luis; Salminen, Seppo; Vinot, Nina; Lebeer, Sarah
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Diverse terms have been used in the literature to refer to the health benefitsobtained from the administration of non-viable microorganisms or their cellfragments and metabolites. In an effort to provide continuity to this emergingfield, the International Scientific Association of Probiotics and Prebiotics (ISAPP)convened a panel of experts to consider this category of substances and adoptedthe term postbiotic, which they defined as a “preparation of inanimatemicroorganisms and/or their components that confers a health benefit on thehost.” This definition does not stipulate any specific health benefit, finishedproduct, target population or regulatory status. In this perspective article, wefocused on postbiotics developed for pharmaceutical uses, including medicinalproducts and medical devices. We address how this field is regulated for productsbased on inanimate microorganisms, marketing considerations and existingexamples of postbiotics products developed as cosmetics for the skin, forvaginal health, and as orally consumed products. We focus on the EuropeanUnion for regulatory aspects, but also give examples from other geographicalareas.
Fil: Vinderola, Celso Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe. Instituto de Lactología Industrial. Universidad Nacional del Litoral. Facultad de Ingeniería Química. Instituto de Lactología Industrial; Argentina
Fil: Druart, Céline. Pharmabiotic Research Institute; Francia
Fil: Gosálbez, Luis. No especifíca;
Fil: Salminen, Seppo. University Of Turku; Finlandia
Fil: Vinot, Nina. No especifíca;
Fil: Lebeer, Sarah. Universiteit Antwerp; Bélgica
Materia
postbiotics
International Scientific Association for Probiotics and Prebiotics
ISAPP
medicinal product
medical device
drug
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/243198
Acceder
id CONICETDig_7d856bfb4f225475040057e59b6c8832
oai_identifier_str oai:ri.conicet.gov.ar:11336/243198
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerationsVinderola, Celso GabrielDruart, CélineGosálbez, LuisSalminen, SeppoVinot, NinaLebeer, SarahpostbioticsInternational Scientific Association for Probiotics and PrebioticsISAPPmedicinal productmedical devicedrughttps://purl.org/becyt/ford/2.11https://purl.org/becyt/ford/2Diverse terms have been used in the literature to refer to the health benefitsobtained from the administration of non-viable microorganisms or their cellfragments and metabolites. In an effort to provide continuity to this emergingfield, the International Scientific Association of Probiotics and Prebiotics (ISAPP)convened a panel of experts to consider this category of substances and adoptedthe term postbiotic, which they defined as a “preparation of inanimatemicroorganisms and/or their components that confers a health benefit on thehost.” This definition does not stipulate any specific health benefit, finishedproduct, target population or regulatory status. In this perspective article, wefocused on postbiotics developed for pharmaceutical uses, including medicinalproducts and medical devices. We address how this field is regulated for productsbased on inanimate microorganisms, marketing considerations and existingexamples of postbiotics products developed as cosmetics for the skin, forvaginal health, and as orally consumed products. We focus on the EuropeanUnion for regulatory aspects, but also give examples from other geographicalareas.Fil: Vinderola, Celso Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe. Instituto de Lactología Industrial. Universidad Nacional del Litoral. Facultad de Ingeniería Química. Instituto de Lactología Industrial; ArgentinaFil: Druart, Céline. Pharmabiotic Research Institute; FranciaFil: Gosálbez, Luis. No especifíca;Fil: Salminen, Seppo. University Of Turku; FinlandiaFil: Vinot, Nina. No especifíca;Fil: Lebeer, Sarah. Universiteit Antwerp; BélgicaFrontiers Media2023-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/243198Vinderola, Celso Gabriel; Druart, Céline; Gosálbez, Luis; Salminen, Seppo; Vinot, Nina; et al.; Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations; Frontiers Media; Frontiers in Pharmacology; 14; 9-2023; 1-61663-9812CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1239745/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fphar.2023.1239745info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:52:34Zoai:ri.conicet.gov.ar:11336/243198instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:52:34.798CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations
title Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations
spellingShingle Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations
Vinderola, Celso Gabriel
postbiotics
International Scientific Association for Probiotics and Prebiotics
ISAPP
medicinal product
medical device
drug
title_short Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations
title_full Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations
title_fullStr Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations
title_full_unstemmed Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations
title_sort Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations
dc.creator.none.fl_str_mv Vinderola, Celso Gabriel
Druart, Céline
Gosálbez, Luis
Salminen, Seppo
Vinot, Nina
Lebeer, Sarah
author Vinderola, Celso Gabriel
author_facet Vinderola, Celso Gabriel
Druart, Céline
Gosálbez, Luis
Salminen, Seppo
Vinot, Nina
Lebeer, Sarah
author_role author
author2 Druart, Céline
Gosálbez, Luis
Salminen, Seppo
Vinot, Nina
Lebeer, Sarah
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv postbiotics
International Scientific Association for Probiotics and Prebiotics
ISAPP
medicinal product
medical device
drug
topic postbiotics
International Scientific Association for Probiotics and Prebiotics
ISAPP
medicinal product
medical device
drug
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.11
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Diverse terms have been used in the literature to refer to the health benefitsobtained from the administration of non-viable microorganisms or their cellfragments and metabolites. In an effort to provide continuity to this emergingfield, the International Scientific Association of Probiotics and Prebiotics (ISAPP)convened a panel of experts to consider this category of substances and adoptedthe term postbiotic, which they defined as a “preparation of inanimatemicroorganisms and/or their components that confers a health benefit on thehost.” This definition does not stipulate any specific health benefit, finishedproduct, target population or regulatory status. In this perspective article, wefocused on postbiotics developed for pharmaceutical uses, including medicinalproducts and medical devices. We address how this field is regulated for productsbased on inanimate microorganisms, marketing considerations and existingexamples of postbiotics products developed as cosmetics for the skin, forvaginal health, and as orally consumed products. We focus on the EuropeanUnion for regulatory aspects, but also give examples from other geographicalareas.
Fil: Vinderola, Celso Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe. Instituto de Lactología Industrial. Universidad Nacional del Litoral. Facultad de Ingeniería Química. Instituto de Lactología Industrial; Argentina
Fil: Druart, Céline. Pharmabiotic Research Institute; Francia
Fil: Gosálbez, Luis. No especifíca;
Fil: Salminen, Seppo. University Of Turku; Finlandia
Fil: Vinot, Nina. No especifíca;
Fil: Lebeer, Sarah. Universiteit Antwerp; Bélgica
description Diverse terms have been used in the literature to refer to the health benefitsobtained from the administration of non-viable microorganisms or their cellfragments and metabolites. In an effort to provide continuity to this emergingfield, the International Scientific Association of Probiotics and Prebiotics (ISAPP)convened a panel of experts to consider this category of substances and adoptedthe term postbiotic, which they defined as a “preparation of inanimatemicroorganisms and/or their components that confers a health benefit on thehost.” This definition does not stipulate any specific health benefit, finishedproduct, target population or regulatory status. In this perspective article, wefocused on postbiotics developed for pharmaceutical uses, including medicinalproducts and medical devices. We address how this field is regulated for productsbased on inanimate microorganisms, marketing considerations and existingexamples of postbiotics products developed as cosmetics for the skin, forvaginal health, and as orally consumed products. We focus on the EuropeanUnion for regulatory aspects, but also give examples from other geographicalareas.
publishDate 2023
dc.date.none.fl_str_mv 2023-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/243198
Vinderola, Celso Gabriel; Druart, Céline; Gosálbez, Luis; Salminen, Seppo; Vinot, Nina; et al.; Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations; Frontiers Media; Frontiers in Pharmacology; 14; 9-2023; 1-6
1663-9812
CONICET Digital
CONICET
url http://hdl.handle.net/11336/243198
identifier_str_mv Vinderola, Celso Gabriel; Druart, Céline; Gosálbez, Luis; Salminen, Seppo; Vinot, Nina; et al.; Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations; Frontiers Media; Frontiers in Pharmacology; 14; 9-2023; 1-6
1663-9812
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1239745/full
info:eu-repo/semantics/altIdentifier/doi/10.3389/fphar.2023.1239745
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269167836725248
score 13.13397

Publicaciones similares